Lower blood 25(OH)D levels might be associated with increased risk of ALRTI in term newborn babies. Appropriate vitamin D supplementation during pregnancy and early childhood may enhance newborns' respiratory health.
Aim To evaluate the relationship between serum 25-hydroxy vitamin D, 25 (OH) D, levels and retinopathy of prematurity. Methods and Results Serum 25 (OH) D levels were measured in 97 very low birth weight infants, prior to vitamin D supplementation. The development of retinopathy of prematurity and its treatment requirement were evaluated. At follow-up, retinopathy of prematurity developed in 71 (73.2%) infants. Serum 25 (OH) D levels were significantly lower in infants with retinopathy of prematurity than ones without retinopathy of prematurity ( P < 0.001). The infants who required treatment had lower 25 (OH) D levels compared with the infants who did not required treatment (7.1 ± 5.2 ng/ml vs. 11.9 ± 6.5 ng/ml; P = 0.003). Multivariate analysis showed that lower serum 25 (OH) D levels may be a risk factor for retinopathy of prematurity development [OR: 1.14, 95% CI (1.02-1.27), P = 0.02]. Conclusion Lower 25 (OH) D levels in the first days of life may be related to retinopathy of prematurity development and treatment requirement in premature infants.
The follow-up of newborns after discharge is key to determine the risks associated with hypernatremic dehydration. Our results suggest that hypernatremic dehydration had no impact on the long-term outcome. In addition, continuous aEEG monitoring could provide information regarding early prognosis and mortality.
Demir eksikliği; aneminin yanı sıra immün bozukluklar, davranış ve entelektüel performans bozukluklarına da yol açarak önemli bir morbidite nedeni olmaktadır. Ülkemizde bir yaş altındaki tüm bebeklere 400 IU/gün D vitamini desteği verilmekte ve bazen bu destek multivitamin olarak yapılmaktadır. Bu dönemde demir eksikliği anemisi (DEA) de sık görülmekte olup, demir tedavisine de başvurulmaktadır. Bu çalışmada DEA olan çocuklarda ferrözsülfat (Fe+2) ve ferrikpolimaltoz (Fe+3) tedavi etkinliklerinin karşılaştırılması ve eşzamanlı verilen multivitamin tedavisinin bu tedaviler üzerine olan etkisi araştırıldı. Gereç ve Yöntemler: Çalışmamızda DEA tanısı alan 200 hasta dört gruba ayrıldı. I. gruba Fe+2 (ferrözsülfat), II. gruba Fe+2 ile eşzamanlı multivitamin, III. gruba Fe+3 (ferrikpolimaltoz) ve IV. gruba Fe+3 ile eşzamanlı multivitamin verildi. Demir tedavisi tüm gruplarda 3 mg/kg/gün üç ay süre ile tek doz olarak uygulandı. Multivitamin tedavisi ise demir tedavisi ile eşzamanlı verildi. Tedavi öncesi, tedavinin 1. ayı ve tedavi sonrası tam kan değerleri ve ferritin düzeylerindeki değişiklikler incelendi.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.